We are extremely concerned that a decision not to add any new technologies in the 23/24 MedTech Funding Mandate was reached at a time when the NHS is under such unparalleled pressure.
New health technologies and digital innovations, such as the ones already used in the NHS through the Mandate, could provide a much-needed lifeline for the NHS by improving patient outcomes and saving clinicians’ time.
Our CEO, Nicholas Lansman, commented on the decision saying “Whilst it is important that the 22/23 technologies are properly implemented across the new ICS structure, this decision slams the door shut on new innovations being supported effectively across the NHS. It undermines the need to improve innovation within the health system and this will harm patient outcomes“.